Inlyta 5 mg is a targeted cancer therapy developed by Pfizer, containing the potent active ingredient Axitinib, designed specifically for the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. This advanced vascular endothelial growth factor receptor (VEGFR) inhibitor is a second-line treatment option, often recommended for patients who have not responded adequately to other therapies like sunitinib or cytokine-based treatments. With its proven efficacy in slowing disease progression and improving patient outcomes, Inlyta 5 mg is widely recognized as a cornerstone treatment in modern oncology.
Key Product Details:
- Active Ingredient: Axitinib 5 mg
- Form: Film-Coated Tablets
- Administration: Oral
- Packaging: 56 Film-Coated Tablets
- Manufacturer: Pfizer
Key Benefits of Inlyta 5 mg:
- Superior Cancer Control: Effectively targets VEGFR-1, VEGFR-2, and VEGFR-3 pathways, inhibiting tumor angiogenesis and reducing blood supply to cancer cells.
- Second-Line Therapy: Specifically designed for patients whose renal cell carcinoma progressed despite prior systemic therapy.
- Improved Progression-Free Survival: Clinical trials have demonstrated that patients treated with Inlyta 5 mg achieved longer progression-free survival compared to alternative treatments.
- Precision Therapy: Focused inhibition of angiogenesis pathways leads to a highly selective anti-tumor effect, reducing damage to healthy tissues.
- Oral Convenience: Inlyta 5 mg offers a simple oral dosage form, providing ease of administration for patients undergoing long-term cancer treatment.
How Does Inlyta 5 mg Work?
Inlyta (Axitinib) is a potent and selective inhibitor of vascular endothelial growth factor receptors (VEGFRs), crucial in the formation of new blood vessels (angiogenesis). Tumors require a robust blood supply to grow and spread; by blocking VEGFR-1, VEGFR-2, and VEGFR-3, Inlyta 5 mg starves the tumor of nutrients and oxygen, thereby slowing or halting tumor growth.
Indications:
- Advanced Renal Cell Carcinoma (RCC): Inlyta 5 mg is indicated for the treatment of patients with advanced kidney cancer who have previously received first-line therapy but experienced disease progression.
Dosage and Administration:
- Initial Dose: 5 mg orally, twice daily (approximately 12 hours apart).
- With or Without Food: Tablets can be taken with or without meals.
- Dosage Adjustment: Based on individual tolerability and efficacy, the dose may be increased to 7 mg or reduced to 3 mg or 2 mg as necessary.
Safety Information:
- Common Side Effects: Hypertension, diarrhea, fatigue, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot syndrome), and decreased appetite.
- Hypertension Risk: Blood pressure monitoring is essential as hypertension is a common side effect.
- Drug Interactions: Caution is advised when used with CYP3A4 inhibitors or inducers.
- Liver Function Monitoring: Liver enzyme levels should be checked regularly during treatment.
Why Choose Inlyta 5 mg?
- Proven Efficacy: Demonstrated in pivotal clinical trials to enhance progression-free survival in patients with advanced RCC.
- Selective VEGFR Inhibition: Targets key angiogenic pathways to suppress tumor growth efficiently.
- Trusted Manufacturer: Produced by Pfizer, a global leader in pharmaceutical innovation and oncology research.
- Patient-Friendly Dosage: Oral formulation with flexible dose adjustments tailored to patient needs.
Storage Conditions:
- Temperature: Store at room temperature (20°C to 25°C).
- Protection: Keep in original packaging to protect from moisture and light.
Buy Inlyta 5 mg Online:
Searching for Inlyta 5 mg (Axitinib) tablets from a reliable source? We offer genuine Pfizer products with secure shipping to your doorstep. Get access to advanced kidney cancer treatment today and take a step towards better health.
Product Short Description:
Değerlendirmeler
Henüz değerlendirme yapılmadı.